The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

AACR 2017 | Poster 2651/10 – huB4-DGN462, a novel CD19 targeting antibody drug conjugate, shows promising activity in CD19+ Lymphoma models

Apr 7, 2017

On Monday 3 rdApril at this year’s American Association for Cancer Research(AACR) annual meeting, a poster ( 2651 / 10) by Eugenio Gaudio, from the Institute of Oncology Research, Bellinzona, Switzerland, et al.titled “A novel CD19 targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models” was presented.

The group investigated the preclinical activity of a novel CD19-specifc ADC, consisting of the humanized anti-CD19 antibody huB4 and DGN462 via a cleavable disulfide linker, sulfo-SPDB. Activity of the huB4-DGN462 ADC or the unconjugated DGN462 toxin was measured in vitrousing a total of 54 Lymphoma cell lines (n = 27 DLBCL; n = 10 MCL; n = 6 MZL; n = 5 ALCL; n = 6 others). Efficacy of huB4-DGN462 was also analyzed in vivoin CD19-expressing xenograft tumor models.

Key Highlights:

  • huB4-DGN462 was cytotoxic in 48 B-cell Lymphoma lines (median IC 50100pM; 95%CI, 38–214)
  • Cytotoxic activity was not associated with DLBCL cell of origin, or limited by P53, BCL2, MYC, or CDKN2A status
  • huB4-DGN462 was significantly ( P= 0.007) less active in 8 TCL lines (median IC 5075nM; 95% CI, 0.5–5.75) than in B-cell Lymphoma; in accordance with the lower CD19 expression in TCLs
  • huB4-DGN462 induced caspase 3/7 activation in 89% (48/54) cell lines
  • In two DLBCL xenograft models (DoHH2 SC model and Farage disseminated model), huB4-DGN462 showed strong anti-tumor activity after a single IV dose
  • In DoHH2 model, at 1.7mg Ab/kg, huB4-DGN462 lead to a significant, dose-dependent delay in tumor growth and survival benefit versusa non-targeted control DGN462 ADC
  • In Farage model, a significant, dose-dependent increase in survival was reported in mice treated with as little as 0.17mg Ab/kg of huB4-DGN462; At 1.7mg Ab/kg, life span increased by >400% versusuntreated mice

The poster concluding by stating that this data indicates that the novel ADC huB4-DGN462 has potent activity in preclinical models, providing cause for further study.

  1. Gaudio E. et al.A novel CD19 targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models [Poster]. In: Proceedings of the 107th Annual Meetingof the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [ 2651 / 10].